## CLAIM AMENDMENTS

1-32. (canceled)

33. (currently amended): A method to deliver a synergistic therapeutically effective amount of a fluoropyrimidine/water-soluble camptothecin drug combination [[by]] to a subject which method comprises administering to said subject a first composition containing a fluoropyrimidine stably associated with a first particulate delivery vehicle and a second composition containing a water-soluble camptothecin stably associated with a second particulate delivery vehicle ~~wherein the ratio of the fluoropyrimidine and the water-soluble camptothecin administered is non-antagonistic~~,

wherein said stable association maintains, for at least one hour, a synergistic ratio of said fluoropyrimidine and camptothecin in the blood when administered *in vivo*, and

wherein said synergistic ratio is such that when said ratio is provided to cancer cells in an *in vitro* assay over the concentration range at which the fraction of affected cells is 0.20 to 1.00, synergy is exhibited over at least 20% of said range.

34. (new): The method of claim 33 wherein the particulate delivery vehicles have a mean diameter of between 4.5 and 500 nm.

35. (new): The method of claim 33 wherein said delivery vehicles comprise

liposomes, and/or
lipid micelles, and/or
block copolymer micelles, and/or
microparticles, and/or
nanoparticles, and/or
polymer lipid hybrid systems, and/or
derivatized single chain polymers.

36. (new): The method of claim 33 wherein the water-soluble camptothecin is irinotecan (CPT-11), topotecan, 9-aminocamptothecin or lurtotecan.

37. (new): The method of claim 33 wherein the water-soluble camptothecin is a hydrophilic salt of a water-insoluble camptothecin.

38. (new): The method of claim 33 wherein the water-soluble camptothecin is irinotecan (CPT-11) or topotecan.

39. (new): The method of claim 33 wherein the fluoropyrimidine is floxuridine, fluorouracil or UFT (tegafur/uracil).

40. (new): The method of claim 33 wherein the water-soluble camptothecin is irinotecan and said fluoropyrimidine is floxuridine or 5-FU.

41. (new): The method of claim 40 wherein the ratio is 1:1.

42. (new): The method of claim 33 which further comprises administering leucovorin to said subject.

43. (new): A kit that comprises a first container containing the first composition and a second container containing the second composition as described in claim 33.

44. (new): The kit of claim 43 wherein the amounts of said first and second compositions in each container are premeasured to provide a synergistic ratio.